Mycovia: Phase III data evaluating Vivjoa in recurrent vulvovaginal candidiasis published in NEJM Evidence
Mycovia Pharmaceuticals announced the publication of positive Phase III data evaluating Vivjoa (oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) in the July edition of NEJM Evidence
Read full article »
CEO
Mycovia's headquarters is in Durham, North Carolina. Mycovia has a revenue of $4.9M, and 24 employees. Mycovia has 2 followers on Owler.